Literature DB >> 3171557

Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers.

E McKay1, P Higgins, D Tyrrell, C Pringle.   

Abstract

Single temperature-sensitive (ts) mutants of a subgroup A strain of respiratory syncytial (RS) virus whose multiplication is restricted at 39 degrees C in MRC-6 cells and double ts mutants that are restricted at 38 degrees C, were obtained following mutagenesis using 5-fluorouracil and acridine-like compounds. Isolation and propagation of the parental RSS-2 strain of RS virus and its derived ts mutants were carried out entirely in MRC-5 human diploid cells. The immunogenicity and disease-producing ability of four of these mutants and the parental unmodified strain have been assessed by intranasal administration into groups of about 20 adult volunteers. The results of these trials indicate that the capacity of the parental RSS-2 strain to produce upper respiratory tract infection in adults was not diminished by limited propagation in MRC-5 cells. The mutants on the other hand were impaired in this respect to varying extents. The double mutant tslB in particular has characteristics that suggest that it may be suitable for further development as a live RS virus vaccine. It retained near normal immunogenicity and replicative ability in the upper respiratory tract, while exhibiting greatly reduced disease-producing potential.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3171557     DOI: 10.1002/jmv.1890250405

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

Review 1.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

Review 2.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment.

Authors:  Saber Yezli; Jonathan A Otter
Journal:  Food Environ Virol       Date:  2011-03-16       Impact factor: 2.778

Review 4.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

6.  Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Authors:  Roderick S Tang; Mia MacPhail; Jeanne H Schickli; Jasmine Kaur; Christopher L Robinson; Heather A Lawlor; Jeanne M Guzzetta; Richard R Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 8.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 9.  Respiratory viral infections in the elderly.

Authors:  J Treanor; A Falsey
Journal:  Antiviral Res       Date:  1999-12-15       Impact factor: 5.970

10.  The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers.

Authors:  P G Higgins; G I Barrow; D A Tyrrell; D Isaacs; C L Gauci
Journal:  Antiviral Res       Date:  1990-07       Impact factor: 5.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.